Page 19 - Ohnson Johnson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

J&J, which currently owns an 89.6% stake in Kenvue, said it intends to split off at least 80.1% of the consumer health company's shares as part of the offering. The offering will help J&J move a step closer in its plan to spin off the unit and focus on its larger medical devices and pharmaceuticals businesses. The exchange will allow J&J shareholders to exchange their shares for those of Kenvue at a 7% discount, subject to conditions.

Johnson & Johnson (NYSE:JNJ) Q2 2023 Earnings Call Transcript July 20, 2023 Johnson & Johnson beats earnings expectations. Reported EPS is $2.8, expectations were $2.62. Operator: Good morning, and welcome to Johnson & Johnson’s Second Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference. […]

Shares of J&J, which recently spun off its consumer health unit to focus on drugs and medical devices, rose over 1% in premarket trading. J&J has placed huge bets on its newer cancer drugs, while trying to bolster growth at its pandemic-hit medical devices business, as it looks to counter a potential slowdown in sales of its blockbuster arthritis drug, Stelara, which faces the threat of competition in 2025.

Key Companies covered in the nicotine gum market report are GlaxoSmithKline plc (U.K.), Johnson & Johnson (U.S.), Novartis Consumer Health (Germany), ITC Limited (India), Cipla Health Limited (India), Perrigo Company Plc (Ireland), Fertin Pharma (Denmark), Alchem International (India), Revolymer (U.K.) and others.Pune, India, July 19, 2023 (GLOBE NEWSWIRE) -- The global nicotine gum market size was valued at USD 1.49 billion in 2021 and is expected to reach USD 2.17 billion by 2029, exhibiting a

We've got a loaded slate, including quarterly results from Netflix, American Express, and Johnson & Johnson. But how do estimates stack up heading into their respective prints?